MARKET

CVM

CVM

CEL SCI
AMEX

Real-time Quotes | Nasdaq Last Sale

20.67
-0.72
-3.37%
After Hours: 20.60 -0.07 -0.34% 18:23 05/10 EDT
OPEN
21.03
PREV CLOSE
21.39
HIGH
21.25
LOW
20.06
VOLUME
451.65K
TURNOVER
--
52 WEEK HIGH
40.91
52 WEEK LOW
10.76
MARKET CAP
837.74M
P/E (TTM)
-23.5448
1D
5D
1M
3M
1Y
5Y
West Nile Virus Infections Medicine Market Global Development, Industry Trends, Demand and Growth Analysis and Forecasts 2021 to 2028 By Ameco Research
pune, India, Fri, 07 May 2021 06:43:43 / Comserve Inc. / -- The global West Nile Virus Infections Medicine market is segmented by company, region (country),...
Comserve · 3d ago
Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90
Investor's Business Daily · 04/28 19:26
Insider Trends: 90-Day Insider Selling Trend Prolonged at Cel-Sci
MT Newswires · 04/26 06:28
FSR, NKLA, CVM and DNMR among midday movers
Gainers: Takung Art (TKAT) +33%.Teradata (TDC) +29%.Renalytix AI (RNLX) +24%.Qualtrics International (XM) +24%.Galectin Therapeutics (GALT) +23%.Kaleido Biosciences (KLDO) +21%.CEL-SCI (CVM) +21%.Novan (NOVN) +20%.Nikola (NKLA) +17%.Equifax (EFX) +17%.Lose...
Seekingalpha · 04/22 16:37
Thursday Sector Leaders: Specialty Retail, Biotechnology Stocks
Apr 22, 2021 (MarketNewsVideo.com via COMTEX) -- In trading on Thursday, specialty retail shares were relative leaders, up on the day by about 3.9%. Leading...
MarketNewsVideo.com · 04/22 16:15
CEL-SCI, Renalytix leads healthcare gainers; Evolus, Precipio among major losers
Gainers: CEL-SCI (CVM) +20%, Renalytix RNLX +19%, Chemomab Therapeutics Ltd. (CMMB) +15%, Brooklyn ImmunoTherapeutics (BTX) +13%, Ocugen OCGN +13%.Losers: Evolus EOLS -18%, Precipio (PRPO) -9%, Shineco (TYHT) -8%, Adagene (ADAG) -6%, Edgewise Therapeutics ...
Seekingalpha · 04/22 15:07
Coronavirus update: J&J vaccine pause remains, Oxford studies blood clots and COVID-19 vaccines
Blood clot concerns lack context, experts say, putting pressure on federal agencies to unpause J&J vaccinations.
Yahoo Finance · 04/15 19:46
We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 04/07 07:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CVM. Analyze the recent business situations of CEL SCI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CVM stock price target is 19.00 with a high estimate of 19.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 5.85M
% Owned: 14.43%
Shares Outstanding: 40.53M
TypeInstitutionsShares
Increased
19
2.66M
New
30
493.48K
Decreased
4
177.55K
Sold Out
3
243.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.20%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chief Executive Officer/Director/Treasurer
Geert Kersten
Senior Vice President/Secretary
Patricia Prichep
Senior Vice President
John Cipriano
Senior Vice President
Daniel Zimmerman
Chief Scientific Officer
Eyal Talor
Independent Director
Bruno Baillavoine
Independent Director
Robert Watson
Independent Director
Peter Young
No Data
About CVM
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Webull offers kinds of CEL-SCI Corporation stock information, including AMEX:CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.